Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy
Detection of positive resection margins in surgical procedures of high-risk prostate cancer is key for minimizing the risk of recurrence. This study aimed at evaluating the accuracy of functional tumor-volume segmentation in intraoperative ex vivo PET/CT for margin assessment in prostate cancer patients undergoing radical prostatectomy. <b>Methods:</b> Seven high-risk prostate cancer patients received [<sup>18</sup>F]PSMA-1007 before radical prostatectomy. After removal of the prostate gland, ex vivo imaging on the AURA 10 PET/CT system was performed, and functional tumor volume was segmented using 4 semiautomatic segmentation methods. Resection margins and volumes were compared with histopathology. Additionally, a supportive phantom study was conducted to assess segmentation accuracy at low radiopharmaceutical activity. <b>Results:</b> Clinically, 18 lesions were analyzed in intraoperative PET/CT. Sensitivity, specificity, and positive and negative predictive values of margin detection were 83%, 100%, 100%, and 92%, respectively, using an iterative thresholding method. In 1 patient, a biochemical recurrence was observed within 1 y of prostate-specific antigen follow-up, and 1 patient underwent adjuvant radiotherapy. The remaining 5 patients were still undergoing prostate-specific antigen follow-up with no evidence of biochemical recurrence. On the basis of a phantom-deduced minimal segmentable activity concentration of approximately 2 kBq/mL, we propose an administered [<sup>18</sup>F]PSMA-1007 activity of at least 1.9 and 0.4 MBq/kg for preoperative and intraoperative injections, respectively. <b>Conclusion:</b> Intraoperative ex vivo PET/CT is a promising modality for intraoperative margin assessment. Prospective trials are needed to further investigate the value of specimen PET/CT-based radioguided surgery in high-risk prostate cancer.
Authors
- Ken Herrmann (ORCID: https://orcid.org/0000-0002-9662-7259)
- Habib Zaidi (ORCID: https://orcid.org/0000-0001-7559-5297)
- Walter Jentzen
- Lukas Püllen (ORCID: https://orcid.org/0000-0001-7505-1740)
- Henning Reis (ORCID: https://orcid.org/0000-0003-1373-5295)
- Jens W. Köllermann (ORCID: https://orcid.org/0000-0001-8495-6621)
- Claudia Kesch (ORCID: https://orcid.org/0000-0002-2656-2664)
- Pedro Fragoso Costa (ORCID: https://orcid.org/0000-0002-8926-4541)
- Ulrich Krafft (ORCID: https://orcid.org/0000-0002-0274-7445)
- David Kersting (ORCID: https://orcid.org/0000-0002-8451-1830)
- Theresa Kahl
- Christopher Darr (ORCID: https://orcid.org/0000-0003-2532-8398)
- Wolfgang P. Fendler (ORCID: https://orcid.org/0000-0002-5106-3584)
- Alexandros Moraitis (ORCID: https://orcid.org/0009-0006-8553-4352)
- Boris Hadaschik (ORCID: https://orcid.org/0000-0002-1052-2692)
- J Kandziora
- Francesco Barbato (ORCID: https://orcid.org/0000-0003-4642-6827)
Institutions
- Goethe University Frankfurt (DE)
- University Hospital of Geneva (CH)
- Essen University Hospital (DE)
- University Hospital Frankfurt (DE)
- West German Heart and Vascular Center Essen (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.2967/jnumed.124.268719
- Citations
- 8
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Endocyte
- Intuitive Surgical
- Flatiron Health
- Y-mAbs Therapeutics
- Deutsche Forschungsgemeinschaft
- Astellas Pharma
- Siemens Healthineers
- Ipsen
- Sirtex Medical
- Cilag